This study will evaluate the subjective and behavioral effects of cannabis products labeled as indica, sativa, or generic.
Have provided written informed consent.
Be between the ages of 21 and 55
Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
Test negative for drugs of abuse including breath alcohol at the screening visit and at clinic admission
Self-reported use of illicit drugs (e.g., amphetamine, cocaine, methamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), ketamine, heroin, psilocybin, prescription medications not prescribed to the person) in the past 30 days.
History of or current evidence of significant medical (e.g., seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
Enrolled in another clinical trial or having received any drug as part of a research study within 30 days prior to dosing.
6
Treatment groupsSee each treatment group below.
Johns Hopkins University
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator